Youbisheng Green Paper AG

  • WKN: A1KRLR
  • ISIN: DE000A1KRLR0
  • Land: Deutschland

Nachricht vom 01.08.2014 | 19:37

Youbisheng Green Paper AG appoints new Chief Executive Officer


Youbisheng Green Paper AG  / Key word(s): Change of Personnel

01.08.2014 19:37

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, 1 August 2014 - Due to the continuing unknown whereabouts of the current Chief Executive Officer of Youbisheng Green Paper AG, Haiming Huang, he was relieved of all of his duties with immediate effect by Supervisory Board decision. At the same time, the Supervisory Board appointed his brother, Haibo Huang, as new Chief Executive Officer who, together with local entrepreneur Lam Nan Lung, already ran the daily business of Youbisheng Green Paper AG within the last weeks. As new CEO, Haibo Huang will be in charge of the operating day-to-day business while Lam Nan Lung will be particularly responsible for the future strategic direction of the company. Youbisheng Green Paper AG currently considers possible ways to service the liquidity needs of the German AG and will publish news considering the Annual General Meeting to be held and the half-year report to be published as soon as the new management of the company has gained a clearer insight into the actual situation. The Supervisory Board particularly expects the new management to provide comprehensive information about the actual financial and cash situation of the group after the resignation of the former CFO David Tsui end of July.
Information and Explaination of the Issuer to this News: For further information please contact: Kirchhoff Consult AG Sebastian Bucher Tel.: +49 (0)40 60 91 86 18 sebastian.bucher@kirchhoff.de Youbisheng Green Paper AG c/o HRG Hansische Revisions-Gesellschaft mbH Wirtschaftsprüfungsgesellschaft Ferdinandstrasse 25 20095 Hamburg contact@youbisheng-greenpaper.de Disclaimer concerning prognoses This communication contains forward-looking statements Forward-looking statements are statements that are not historical facts instead they reflect the current views and expectations of Youbisheng Green Paper AG and the assumptions underlying them about future events. Forward-looking statements are subject to many risks and uncertainties. If any of such risks and uncertainties materialize or if the assumptions underlying any of the forward-looking statements of Youbisheng Green Paper AG are proving to be incorrect, the actual results of Youbisheng Green Paper AG may be materially different from those expressed or implied by such forward-looking statements. Youbisheng Green Paper AG does not intend or assume any obligation to update these forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made. 01.08.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: Youbisheng Green Paper AG c/o HRG Hansische Revisions-Gesellschaft, Ferdinandstraße 25 20059 Hamburg Germany Phone: +49 (0)40 60 91 86 0 Fax: +49 (0)40 60 91 86 60 E-mail: ir@youbisheng-greenpaper.de Internet: www.youbisheng-greenpaper.de ISIN: DE000A1KRLR0 WKN: A1KRLR Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf End of Announcement DGAP News-Service

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021